Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Anshul Shah, Jonathan C Tosh, Apoorva Ambavane, Andreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin, Boris Gorsh, Eric M Maiese & Feng Wang. (2021) Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. ClinicoEconomics and Outcomes Research 13, pages 789-800.
Read now
Read now
Andreas Nikolaou, Apoorva Ambavane, Anshul Shah, Wenkang Ma, Jon Tosh, Venediktos Kapetanakis, Jenny Willson, Feng Wang, Cosmina Hogea, Boris Gorsh, Ben Gutierrez, Sandhya Sapra, Attaya Suvannasankha & Yevgeniy Samyshkin. (2021) Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis. Expert Review of Hematology 14:12, pages 1137-1145.
Read now
Read now
Gihan Hamdy Elsisi, João L. Carapinha, Rania Afify, Mohamed Abd Elmoty & Mohamed Khalaf. (2020) A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients. Journal of Medical Economics 23:10, pages 1168-1175.
Read now
Read now
Joanna P. MacEwan, Katharine Batt, Wes Yin, Desi Peneva, Steve Sison, Seanna Vine & Clara Chen. (2018) Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leukemia & Lymphoma 59:4, pages 941-949.
Read now
Read now
Andrzej J. Jakubowiak, Marco Campioni, Ágnes Benedict, Ivan Houisse, Eszter Tichy, Andromachi Giannopoulou, Sanjay K. Aggarwal, Beth L. Barber & Sumeet Panjabi. (2016) Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. Journal of Medical Economics 19:11, pages 1061-1074.
Read now
Read now
Jing Wang, Hongfeng Guo & Xin Zhou. (2015) Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients. OncoTargets and Therapy 8, pages 1277-1284.
Read now
Read now
Chan Shen, Chun-Ru Chien, Daniel M Geynisman, Fabrice Smieliauskas & Ya-Chen T Shih. (2014) A review of economic impact of targeted oral anticancer medications. Expert Review of Pharmacoeconomics & Outcomes Research 14:1, pages 45-69.
Read now
Read now
Articles from other publishers (14)
Larysa SanchezAjai ChariMu ChengDasha CherepanovMaral DerSarkissianFei HuangDawn Marie StullJonathan DaboraMelanie YoungStephen J. NogaSelina PiMelody ZhangAzeem BanatwalaMei Sheng DuhSikander Ailawadhi. (2023) Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. Journal of Managed Care & Specialty Pharmacy 29:11, pages 1205-1218.
Crossref
Crossref
Lineo Marie Matsela, Susan Cleary & Thomas Wilkinson. (2022) Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective. Cost Effectiveness and Resource Allocation 20:1.
Crossref
Crossref
Binod Dhakal, Ravi K. Narra, Smith Giri, Aniko Szabo, Timothy L. Smunt, Sanjoy Ghose, Lakshmi Kant Pathak, Madan Aryal, Mehdi Hamadani, Saurabh Chhabra, Siegfried Janz, Anita D’Souza & Parameswaran N. Hari. (2020) Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta‐analysis of phase 3 randomized controlled trials. Cancer 126:12, pages 2791-2801.
Crossref
Crossref
Jane F. Thompson, Zoe Teh, Yiyang Chen, Joanne Gardiner, Jana M. Bednarz, Geoffrey N. Thompson, Cindy Lee, Noemi Horvath, Peter Bardy & David Yeung. (2020) A costing study of bortezomib shows equivalence of its real‐world costs to conventional treatment. British Journal of Haematology 189:3.
Crossref
Crossref
Ajaikumar B Kunnumakkara, Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Nand Kishor Roy, Krishan Kumar Thakur, Kishore Banik, Mehdi Shakibaei, Subash C Gupta & Bharat B Aggarwal. (2019) Cancer drug development: The missing links. Experimental Biology and Medicine 244:8, pages 663-689.
Crossref
Crossref
Tian-tian Zhang, Sen Wang, Ning Wan, Li Zhang, Zugui Zhang & Jie Jiang. (2018) Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Therapeutics 40:7, pages 1122-1139.
Crossref
Crossref
Lisa Bloudek, Anuja Roy, Jonathan K. Kish, David S. Siegel, Sundar Jagannath, Denise Globe, Laurie Orloski & Emil T. Kuriakose. (2016) Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model. Journal of Managed Care & Specialty Pharmacy 22:8, pages 991-1002.
Crossref
Crossref
SABNA RAJEEV KRISHNAN, RITU JAISWAL, ROSS D. BROWN, FREDERICK LUK & MARY BEBAWY. (2016) Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). International Journal of Oncology 49:1, pages 33-50.
Crossref
Crossref
Karen Lien, Matthew C. Cheung & Kelvin K.W. Chan. (2016) Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. Journal of Oncology Practice 12:4, pages e369-e379.
Crossref
Crossref
Sarah Gooding, I-Jun Lau, Mimi Sheikh, Pamela Roberts, Julia Wong, Emmy Dickens, Ash Bullement, Jamie Elvidge, Dawn Lee & Karthik Ramasamy. (2015) Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. PLOS ONE 10:9, pages e0136207.
Crossref
Crossref
Darius LakdawallaJason ShafrinClaudio LucarelliSean NicholsonZeba M. KhanTomas J. Philipson. (2015) Quality-Adjusted Cost Of Care: A Meaningful Way To Measure Growth In Innovation Cost Versus The Value Of Health Gains. Health Affairs 34:4, pages 555-561.
Crossref
Crossref
Ahmed E. Goda, Raymond L. Erikson, Toshiyuki Sakai, Jong-Seog Ahn & Bo-Yeon Kim. (2015) Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies. Molecular Oncology 9:1, pages 309-322.
Crossref
Crossref
Don RobinsonJrJr, Matthew Reynolds, Corey Casper, Angela Dispenzieri, Jessica Vermeulen, Krista Payne, Judy Schramm, Kay Ristow, Marie-Pierre Desrosiers, Karen Yeomans, Dana Teltsch, Richard Swain, Thomas M. Habermann, Philip Rotella & Helgi Van de Velde. (2014) Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. British Journal of Haematology 165:1, pages 39-48.
Crossref
Crossref
Angela DispenzieriA. Keith Stewart, Asher Chanan-Khan, S. Vincent RajkumarRobert A. KyleRafael Fonseca, Prashant KapoorP. Leif Bergsagel, Arleigh McCurdyMorie A. GertzMartha Q. LacyJohn A. LustStephen J. RussellSteven R. ZeldenrustCraig Reeder, Vivek Roy, Francis BuadiDavid DingliSuzanne R. HaymanNelson LeungYi LinJoseph Mikhael & Shaji K. Kumar. (2013) Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood 122:26, pages 4172-4181.
Crossref
Crossref